摘要
目的探讨麝香保心丸联合吲达帕胺治疗冠心病合并高血压的临床疗效及对血压水平、心功能的影响。方法选取2020年1—12月该院收治的126例冠心病合并高血压患者,按随机数字表法分为两组,各63例。对照组口服吲达帕胺治疗,观察组加用麝香保心丸治疗,持续用药3个月。比较两组临床疗效、血压水平[收缩压(SBP)、舒张压(DBP)]、心功能指标[左室射血分数(LVEF)、左室舒张末内径(LVEDD)、左室收缩末内径(LVESD)]、血管内皮功能[内皮素-1(ET-1)、一氧化氮(NO)]及不良反应发生情况。结果观察组总有效率高于对照组,差异有统计学意义(χ^(2)=4.203,P=0.040);观察组治疗后SBP、DBP水平为(127.58±8.96)、(80.36±6.57)mmHg,低于对照组的(134.42±9.15)、(85.79±6.78)mmHg,差异有统计学意义(t=4.239、4.565,P<0.001);观察组治疗后LVEF为(54.69±5.14)%,高于对照组的(49.01±5.02)%,LVEDD、LVESD为(49.85±4.72)、(35.96±4.03)mm,低于对照组的(54.12±5.06)、(40.35±4.17)mm,差异有统计学意义(t=6.275、4.898、6.009,P<0.001);观察组治疗后ET-1为(52.46±5.17)ng/L,低于对照组的(60.15±5.48)ng/L,NO为(68.96±6.73)μmol/L,高于对照组的(62.37±6.51)μmol/L,差异有统计学意义(t=8.102、5.586,P<0.001);两组不良反应相比,差异无统计学意义(P>0.05)。结论麝香保心丸联合吲达帕胺可降低冠心病合并高血压患者血压水平,减轻心功能损伤,纠正血管内皮功能异常,安全可靠。
Objective To investigate the clinical efficacy of Shexiang Baoxin Pills combined with indapamide in the treatment of coronary heart disease complicated with hypertension and its effects on blood pressure and cardiac function.Methods 126 patients with coronary heart disease and hypertension admitted to the hospital from January to December 2020 were selected and divided into two groups according to the random number table method,with 63 cases in each group.The control group was treated with indapamide orally,and the observation group was treated with Shexiang Baoxin Pills for 3 months.To compare the clinical efficacy,blood pressure level[systolic blood pressure(SBP),diastolic blood pressure(DBP)],cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end diastolic inner diameter(LVEDD),left ventricular end systolic inner diameter(LVESD)],vascular endothelial function[endothelin-1(ET-1),nitric oxide(NO)]and the occurrence of adverse reactions.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(χ^(2)=4.203,P=0.040);the levels of SBP and DBP in the observation group after treatment were(127.58±8.96)mmHg and(80.36±6.57)mmHg,which were lower than the control group(134.42±9.15)mmHg and(85.79±6.78)mmHg,the difference was statistically significant(t=4.239,4.565,P<0.001);the observation group after treatment LVEF was(54.69±5.14)%,which was higher than(49.01±5.02)% of the control group,LVEDD and LVESD were(49.85±4.72)mm and(35.96±4.03)mm,which were lower than those of the control group(54.12±5.06)mm and(40.35±4.17)mm,the difference was statistically significant(t=6.275,4.898,6.009,P<0.001);ET-1 of the observation group after treatment was(52.46±5.17)ng/L,which was lower than that of the control group(60.15±5.48)ng/L,NO was(68.96±6.73)μmol/L,which was higher than the control group(62.37±6.51)μmol/L,the difference was statistically significant(t=8.102,5.586,P<0.001);compared with the two gr
作者
陈震
刘贺
CHEN Zhen;LIU He(Department of Cardiology,Xuzhou Central Hospital,Xuzhou,Jiangsu Province,221000 China)
出处
《系统医学》
2021年第23期44-47,共4页
Systems Medicine
关键词
冠心病
高血压
麝香保心丸
吲达帕胺
心功能
血管内皮功能
Coronary heart disease
Hypertension
Shexiang Baoxin Pills
Indapamide
Heart function
Vascular endothelial function
